Latest Safety News

CuFe Ltd has enhanced the confidence level of its Orlando deposit resource at Tennant Creek, increasing the Indicated classification from 42% to 56% following a rigorous QAQC review. This upgrade supports the imminent release of the Orlando Scoping Study.

Clarity Pharmaceuticals has successfully completed recruitment for its pivotal Co-PSMA Phase II trial, testing its novel Cu-SAR-bisPSMA diagnostic against the current standard in detecting prostate cancer recurrence. This milestone advances their mission to improve early detection and treatment outcomes for men with low PSA levels.

Visionflex Group delivered a standout Q4 FY25, posting $2.1 million in cash receipts and securing transformative contracts that underpin its expanding virtual healthcare footprint.

29Metals Limited's June Quarter 2025 report highlights steady production at Golden Grove with revised capital guidance, while Capricorn Copper remains suspended but progresses on key environmental and regulatory fronts.

29Metals Limited reported a stronger June quarter with increased copper production at Golden Grove, offset by higher costs and deferred capital spending on the Gossan Valley project. The company also secured a final $54 million insurance payout and improved liquidity despite ongoing operational challenges at Capricorn Copper.

Genesis Minerals delivered record FY25 gold production, exceeding guidance, and completed a transformative A$250 million acquisition of Focus Minerals’ Laverton project, enhancing its ASPIRE 400 growth strategy.

ClearVue Technologies’ solar façade trial at Hong Kong EMSD headquarters reveals a rapid 2.6-year payback period with government incentives, alongside strong thermal and fire safety performance.

Alliance Nickel has strengthened its financial position with an additional A$1.2 million unsecured loan and extended existing facilities, while reaffirming the commercial viability of its NiWest Nickel-Cobalt Project through a comprehensive Definitive Feasibility Study.

Prescient Therapeutics has initiated its first US clinical site for the PTX-100 Phase 2a trial targeting Cutaneous T-Cell Lymphoma, marking a key milestone in expanding patient recruitment beyond Australia.

Phoslock Environmental Technologies reported a $474,000 cashflow deficit in Q2 2025, with sales impacted by deferred European projects and ongoing US tariff uncertainties. Factory refurbishment delays push production restart to early 2026.

dorsaVi confirms its licensed 40nm Resistive RAM technology delivers high-speed, low-power performance ideal for next-generation embedded and edge AI platforms. This breakthrough supports advanced wearable sensors and neuromorphic computing applications.

Li-S Energy has appointed Paladin Defense Services as its U.S. representative to accelerate engagement with the Department of Defense and defence contractors, aiming to commercialise its advanced battery technology in a critical market.